Garry Michael Walsh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Garry Michael Walsh has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Darren W. Sexton
Liverpool John Moores University
7 shared publications M. G. Blaylock
Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK
4 shared publicationsA. Lawrie
2 shared publications- Andrew John Wardlaw
University of Leicester
2 shared publications Helene F. Rosenberg
National Institute of Allergy and Infectious Diseases, National Institutes of Health
2 shared publicationsL. Thomson
Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK
2 shared publications
Latest Publications
- Open Access
- 2 March 2026
- Published by Open Exploration Publishing in Exploration of asthma & allergy
- Vol. 4, 1009111
UpToDate on eosinophils
This review describes the eosinophil journey through the various physiological and pathophysiological phases, from production, maturation, and activation by chemokines and cytokines [especially eotaxin, interleukin (IL)-5, IL-3, and granulocyte-macrophage colony-stimulating factor (GM-CSF)], to interaction with the innate and adaptive immune system and tissue homing. Excessive production and activation of eosinophils lead to the release of granule proteins, such as major basic protein, eosinophil cationic protein, eosinophil peroxidase, and others, resulting in inflammation, cell cytotoxicity, and oxidative stress. The pathogenesis, clinical features, diagnostic processes, and the latest therapeutic approaches to the resulting diseases—which affect the upper and lower airways, gastrointestinal tract, skin, myocardium, and may occur systemically—are discussed.
- 2 March 2026
- Published by Open Exploration Publishing in Exploration of asthma & allergy
- Vol. 4, 1009111
Open AccessUpToDate on eosinophils
This review describes the eosinophil journey through the various physiological and pathophysiological phases, from production, maturation, and activation by chemokines and cytokines [especially eotaxin, interleukin (IL)-5, IL-3, and granulocyte-macrophage colony-stimulating factor (GM-CSF)], to interaction with the innate and adaptive immune system and tissue homing. Excessive production and activation of eosinophils lead to the release of granule proteins, such as major basic protein, eosinophil cationic protein, eosinophil peroxidase, and others, resulting in inflammation, cell cytotoxicity, and oxidative stress. The pathogenesis, clinical features, diagnostic processes, and the latest therapeutic approaches to the resulting diseases—which affect the upper and lower airways, gastrointestinal tract, skin, myocardium, and may occur systemically—are discussed.
- Open Access
- 25 November 2025
- Published by MDPI AG in Antibodies
- Vol. 14 (4) , 101
Recent Developments in Monoclonal-Antibody-Based Biologic Therapy for Severe Refractory Eosinophilic Asthma
Background: Asthma exhibits marked heterogeneity both clinically and at the molecular phenotypic level, requiring specifically targeted treatments to block the key pathways of the disease. Monoclonal-antibody-based biologics targeted at critical inflammatory pathways of T2 inflammation such as IL-5, IL-5R, IL-4, and IL-13 are increasingly regarded as effective treatments for severe refractory eosinophilic asthma. Methods: This review provides an update on the potential of straightforward and reproducible biomarkers to aid in the selection of the biologic-based therapy most likely to be effective in patients with severe or refractory eosinophilic asthma based on English-language original articles in PubMed or MedLine. Results: Monoclonal-antibody-based biologic therapies have revolutionised severe asthma management, enabling reductions in symptoms that include exacerbations, discontinuation of oral corticosteroids, improved lung function, and enhanced quality of life. Significant clinical effects with anti-IL-5 or -IL-4/13 monoclonal antibodies are more likely to be seen when simple predictive biomarkers such as serum periostin, fractional exhaled nitric oxide (FENO), or blood eosinophil counts are used to aid in the identification of those patients with severe refractory eosinophilic asthma who are most likely to benefit from biologic therapies. Conclusions: Biologic-based therapy aimed at T2 inflammation benefits patients with severe eosinophilic asthma, particularly when guided by biomarkers that do not require direct sampling of the airways to target therapy, who are most likely to benefit from these treatments, with good safety profiles for these therapies.
- 25 November 2025
- Published by MDPI AG in Antibodies
- Vol. 14 (4) , 101
Open AccessRecent Developments in Monoclonal-Antibody-Based Biologic Therapy for Severe Refractory Eosinophilic Asthma
Background: Asthma exhibits marked heterogeneity both clinically and at the molecular phenotypic level, requiring specifically targeted treatments to block the key pathways of the disease. Monoclonal-antibody-based biologics targeted at critical inflammatory pathways of T2 inflammation such as IL-5, IL-5R, IL-4, and IL-13 are increasingly regarded as effective treatments for severe refractory eosinophilic asthma. Methods: This review provides an update on the potential of straightforward and reproducible biomarkers to aid in the selection of the biologic-based therapy most likely to be effective in patients with severe or refractory eosinophilic asthma based on English-language original articles in PubMed or MedLine. Results: Monoclonal-antibody-based biologic therapies have revolutionised severe asthma management, enabling reductions in symptoms that include exacerbations, discontinuation of oral corticosteroids, improved lung function, and enhanced quality of life. Significant clinical effects with anti-IL-5 or -IL-4/13 monoclonal antibodies are more likely to be seen when simple predictive biomarkers such as serum periostin, fractional exhaled nitric oxide (FENO), or blood eosinophil counts are used to aid in the identification of those patients with severe refractory eosinophilic asthma who are most likely to benefit from biologic therapies. Conclusions: Biologic-based therapy aimed at T2 inflammation benefits patients with severe eosinophilic asthma, particularly when guided by biomarkers that do not require direct sampling of the airways to target therapy, who are most likely to benefit from these treatments, with good safety profiles for these therapies.
- Open Access
- 1 March 2025
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 21, 383-384
Therapeutics and Clinical Risk Management - 20th Anniversary
Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articlesor submit your research for publishing
- 1 March 2025
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 21, 383-384
Open AccessTherapeutics and Clinical Risk Management - 20th Anniversary
Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articlesor submit your research for publishing
- 27 April 2023
- Published by Elsevier
- Vol. 98, 31-54
Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment
- 27 April 2023
- Published by Elsevier
- Vol. 98, 31-54
Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment
- 24 January 2021
- Published by Springer Nature
- Vol. 2241, 1-14
Molecular Biology of Eosinophils: Introduction
The eosinophil is an enigmatic cell with a continuing ability to fascinate. A considerable history of research endeavor on eosinophil biology stretches from the present time back to the nineteenth century. Perhaps one of the most fascinating aspects of the eosinophil is how accumulating knowledge has changed the perception of its function from passive bystander, modulator of inflammation, to potent effector cell loaded with histotoxic substances through to more recent recognition that it can act as both a positive and negative regulator of complex events in both innate and adaptive immunity. This book consists of chapters written by experts in the field of eosinophil biology that provide comprehensive clearly written protocols for techniques designed to underpin research into the function of the eosinophil in health and disease.
- 24 January 2021
- Published by Springer Nature
- Vol. 2241, 1-14
Molecular Biology of Eosinophils: Introduction
The eosinophil is an enigmatic cell with a continuing ability to fascinate. A considerable history of research endeavor on eosinophil biology stretches from the present time back to the nineteenth century. Perhaps one of the most fascinating aspects of the eosinophil is how accumulating knowledge has changed the perception of its function from passive bystander, modulator of inflammation, to potent effector cell loaded with histotoxic substances through to more recent recognition that it can act as both a positive and negative regulator of complex events in both innate and adaptive immunity. This book consists of chapters written by experts in the field of eosinophil biology that provide comprehensive clearly written protocols for techniques designed to underpin research into the function of the eosinophil in health and disease.
- 18 August 2020
- Published by Taylor & Francis
- p. 187-199
Eosinophil Interactions with Extracellular Matrix Proteins
Tissue infiltration by often large numbers of eosinophils is one of the consistent features of asthma and related diseases such as allergic rhinitis or atopic dermatitis (1,2). The ability of eosinophils to generate an array of pro-inflammatory mediators, in particular the cytotoxic granule proteins such as eosinophil major basic protein (MBP), has led to the hypothesis that asthma is an ongoing mucosal inflammatory disease, a major component of which is the tissue damage mediated by eosinophil-derived mediators (3,4). The mechanisms responsible for selective eosinophil accumulation in the airways in asthma are complex but probably involve a combination of selective adhesion to bronchial postcapillary venular endothelium, followed by transmigration into the bronchial submucosa under the influence of chemotactic factors such as platelet-activating factor (PAF), leukotriene B4, and C-C chemokines such as regulated on activation, normal T cell expressed and secreted (RANTES) (5,6).
- 18 August 2020
- Published by Taylor & Francis
- p. 187-199
Eosinophil Interactions with Extracellular Matrix Proteins
Tissue infiltration by often large numbers of eosinophils is one of the consistent features of asthma and related diseases such as allergic rhinitis or atopic dermatitis (1,2). The ability of eosinophils to generate an array of pro-inflammatory mediators, in particular the cytotoxic granule proteins such as eosinophil major basic protein (MBP), has led to the hypothesis that asthma is an ongoing mucosal inflammatory disease, a major component of which is the tissue damage mediated by eosinophil-derived mediators (3,4). The mechanisms responsible for selective eosinophil accumulation in the airways in asthma are complex but probably involve a combination of selective adhesion to bronchial postcapillary venular endothelium, followed by transmigration into the bronchial submucosa under the influence of chemotactic factors such as platelet-activating factor (PAF), leukotriene B4, and C-C chemokines such as regulated on activation, normal T cell expressed and secreted (RANTES) (5,6).
- 25 June 2020
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 20 (10) , 1237-1244
Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update
Asthma exhibits marked heterogeneity in symptoms with severe or refractory asthma representing a clear area of unmet medical need. These patients require more specifically targeted treatments with ...
- 25 June 2020
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 20 (10) , 1237-1244
Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update
Asthma exhibits marked heterogeneity in symptoms with severe or refractory asthma representing a clear area of unmet medical need. These patients require more specifically targeted treatments with ...
- 17 September 2018
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 12 (11) , 957-963
Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma
Severe or refractory asthma is seen in approximately 5% of asthmatic subjects who have unsatisfactory symptom control despite adherence to high-dose inhaled glucocorticoid therapies resulting in significant morbidity, reduced quality of life and health-care cost implications. Asthma exhibits marked heterogeneity both clinically and at the molecular phenotypic level requiring specifically targeted treatments to block the key pathways of the disease. Monoclonal antibody-based biologics targeted at inhibition of the type 2 cytokines IL-4, IL-5, and IL-13 have considerable potential as effective treatments for severe asthma. Areas covered: This review is based on recent English-language original articles in PubMed or Medline that reported significant clinical findings on the current status, therapeutic potential, and safety of biologics targeted at IL-4, IL-5, and IL-13 in the treatment of asthma together with the potential utility of simple reproducible non-invasive biomarkers to guide the effective use of biologic-based therapy that do not require direct sampling of the airways Expert commentary: The further development of reproducible and straightforward discriminatory non-invasive biomarkers may aid identification of those patients most likely to benefit from treatment with these interventions.
- 17 September 2018
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 12 (11) , 957-963
Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma
Severe or refractory asthma is seen in approximately 5% of asthmatic subjects who have unsatisfactory symptom control despite adherence to high-dose inhaled glucocorticoid therapies resulting in significant morbidity, reduced quality of life and health-care cost implications. Asthma exhibits marked heterogeneity both clinically and at the molecular phenotypic level requiring specifically targeted treatments to block the key pathways of the disease. Monoclonal antibody-based biologics targeted at inhibition of the type 2 cytokines IL-4, IL-5, and IL-13 have considerable potential as effective treatments for severe asthma. Areas covered: This review is based on recent English-language original articles in PubMed or Medline that reported significant clinical findings on the current status, therapeutic potential, and safety of biologics targeted at IL-4, IL-5, and IL-13 in the treatment of asthma together with the potential utility of simple reproducible non-invasive biomarkers to guide the effective use of biologic-based therapy that do not require direct sampling of the airways Expert commentary: The further development of reproducible and straightforward discriminatory non-invasive biomarkers may aid identification of those patients most likely to benefit from treatment with these interventions.
- 20 March 2018
- Published by Taylor & Francis in Immunotherapy
- Vol. 10 (8) , 695-698
Reslizumab in the Treatment of Severe Eosinophilic Asthma: an Update
A marked heterogeneity is exhibited by asthma both clinically and at the molecular level with different phenotypes driven by diverse mechanistic pathways that require specifically targeted treatments. Biologics aimed at IL-4/13, IL-5 or IgE are proven or potentially effective treatments for patients with difficult to treat eosinophilic asthma. Importantly, it is now widely accepted that biologic-based therapies give significant clinical improvements in those patient populations where asthma phenotypes are taken into account. Such asthma phenotypes have been identified by reproducible and straightforward discriminatory biomarkers. This short review discusses recent studies of the effectiveness of the anti-IL-5 reslizumab in relation to the use of simple reproducible biomarkers in eosinophilic asthma.
- 20 March 2018
- Published by Taylor & Francis in Immunotherapy
- Vol. 10 (8) , 695-698
Reslizumab in the Treatment of Severe Eosinophilic Asthma: an Update
A marked heterogeneity is exhibited by asthma both clinically and at the molecular level with different phenotypes driven by diverse mechanistic pathways that require specifically targeted treatments. Biologics aimed at IL-4/13, IL-5 or IgE are proven or potentially effective treatments for patients with difficult to treat eosinophilic asthma. Importantly, it is now widely accepted that biologic-based therapies give significant clinical improvements in those patient populations where asthma phenotypes are taken into account. Such asthma phenotypes have been identified by reproducible and straightforward discriminatory biomarkers. This short review discusses recent studies of the effectiveness of the anti-IL-5 reslizumab in relation to the use of simple reproducible biomarkers in eosinophilic asthma.
- Open Access
- 1 December 2016
- Published by European Medical Group in EMJ. Gastroenterology
- Vol. 5 (1) , 125-129
Monoclonal Antibody-Based Therapy for Eosinophilic Oesophagitis
Eosinophilic oesophagitis is an inflammatory condition associated with marked eosinophil accumulation in the mucosal tissues of the oesophagus.
- 1 December 2016
- Published by European Medical Group in EMJ. Gastroenterology
- Vol. 5 (1) , 125-129
Open AccessMonoclonal Antibody-Based Therapy for Eosinophilic Oesophagitis
Eosinophilic oesophagitis is an inflammatory condition associated with marked eosinophil accumulation in the mucosal tissues of the oesophagus.